We test the anti-myeloma efficacy of 6-OAP on 4 cell lines (U266, RPMI 8226, MM.1S and MM.1R) and CD138+ primary cells harvested from MM patients. This evidence concerns the gene SDC1 and Miyoshi myopathy.